Study of MK0677 for the Treatment of Alzheimer's Disease (0677-030)(COMPLETED)

Study of the Effect of SR57667B in Patients With Alzheimer's Disease

NCT00285025 ·Status: COMPLETED ·Phase: PHASE2

A Study to Evaluate the Effects of MK-0249 and an Alzheimer's Disease Medication on Cognitive Function in Adults With Alzheimer's Disease (MK-0249-023)

NCT00874939 ·Status: TERMINATED ·Phase: PHASE1

Multiple Dose Trial of MK-4334 in Participants With Alzheimer's Clinical Syndrome (MK-4334-005)

NCT03740178 ·Status: WITHDRAWN ·Phase: PHASE1

A Trial of SHR-1707 Infusion in Patients With Mild Cognitive Impairment Due to Alzheimer's Disease and Mild Alzheimer's Disease

NCT06114745 ·Status: COMPLETED ·Phase: PHASE1

Efficacy Study of MPC-7869 to Treat Patients With Alzheimer's

NCT00105547 ·Status: COMPLETED ·Phase: PHASE3

Efficacy and Safety of MK-1942 as an Adjunct Therapy in Participants With Mild to Moderate Alzheimer's Disease Dementia (MK-1942-008)

NCT05602727 ·Status: TERMINATED ·Phase: PHASE2

Efficacy and Safety of MK-7622 as Adjunct Therapy in Participants With Alzheimer's Disease (MK-7622-012)

NCT01852110 ·Status: TERMINATED ·Phase: PHASE2

A Study of the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anti-Abeta (MABT5102A) in Patients With Alzheimer's Disease

NCT00736775 ·Status: COMPLETED ·Phase: PHASE1

Long-Term Safety Extension With SR57667B in Patients With Alzheimer's Disease

NCT00285077 ·Status: COMPLETED ·Phase: PHASE2

A Clinical Trial of AAV2-BDNF Gene Therapy in Early Alzheimer's Disease and Mild Cognitive Impairment

NCT05040217 ·Status: RECRUITING ·Phase: PHASE1

Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease

NCT00663936 ·Status: COMPLETED ·Phase: PHASE2

A Clinical Trial to Compare Forms of MK-1167 in Healthy People (MK-1167-011)

NCT07334860 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1

MK0952 in Patients With Mild-to-Moderate Alzheimer's Disease (0952-004)(COMPLETED)

NCT00362024 ·Status: TERMINATED ·Phase: PHASE2

Elpipodect (MK-8189) Safety and Tolerability in Participants With Alzheimer's Disease With or Without Symptoms of Agitation-Aggression and/or Psychosis (MK-8189-017)

NCT05227118 ·Status: COMPLETED ·Phase: PHASE1

Efficacy and Safety of 26-Week Treatment of AR1001 in Patients With Mild to Moderate Alzheimer's Disease

NCT03625622 ·Status: COMPLETED ·Phase: PHASE2

Efficacy and Safety of T-817MA in Patients With Mild to Moderate Alzheimer's Disease (US202)

NCT02079909 ·Status: COMPLETED ·Phase: PHASE2

Cognition Platform Study in Participants at Risk for Alzheimer's Disease (AD) (MK-0000-413)

NCT04730635 ·Status: COMPLETED ·Phase: PHASE1

The Safety and Efficacy of an Investigational Drug in Delaying the Progression of Alzheimer's Disease

NCT00006187 ·Status: TERMINATED ·Phase: PHASE3

A Study of the Safety, Tolerability, and Pharmacodynamics of MK-8931 in Participants With Alzheimer's Disease (MK-8931-010 AM1 [P07820 AM1])

NCT01496170 ·Status: COMPLETED ·Phase: PHASE1

A Clinical Study to Assess Single and Repeat Doses of a New Medication (GSK933776) in Patients With Alzheimer's Disease

NCT00459550 ·Status: COMPLETED ·Phase: PHASE1

Clinical Trial In Healthy Volunteers And Health Elderly Volunteers To Evaluate The Safety, Tolerability And Blood Concentration After Single And Multiple Escalating Oral Doses Of PF-06751979.

NCT02793232 ·Status: COMPLETED ·Phase: PHASE1

Clinical Pharmacology of p38 MAP Kinase Inhibitor, VX-745, in Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD

NCT02423200 ·Status: COMPLETED ·Phase: PHASE2

A Randomized Study to Evaluate FK962 in Subjects With Mild to Moderate Alzheimer's Disease

NCT00087724 ·Status: TERMINATED ·Phase: PHASE2

Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease

NCT02907567 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Single-Ascending-Dose Study of BIIB076 in Healthy Volunteers and Participants With Alzheimer's Disease

NCT03056729 ·Status: COMPLETED ·Phase: PHASE1